Translating molecular approaches for the detection and evaluation of minimal residual disease kinetics in childhood acute lymphoblastic leukaemia

Abstract

Childhood acute lymphoblastic leukaemia (ALL) is the leading cause of cancer-linked mortality identified in children. Approximately 80% of patients are successfully treated. However, 20-25% of patients will still go on to relapse, including patients in the standard risk groups with no known risk factors at diagnosis. In addition, it is estimated that a further 20-25% of children may be successfully treated using less intensive treatment, thereby reducing treatment related toxicity.